Congress admits biosafety gaps

This in from news editor Alla Katsnelson: At a congressional hearing on linkurl:biosafety;http://www.the-scientist.com/news/display/53626/ today (October 4), the Government Accountability Office reported that the federal government doesn't know how many labs are involved in biosafety level 3 and level 4 work, or where those labs are. Although labs working with certain "select agents" are under the oversight of the CDC, labs working with other pathogens such as SARS or Hantavirus a

By | October 4, 2007

This in from news editor Alla Katsnelson: At a congressional hearing on linkurl:biosafety;http://www.the-scientist.com/news/display/53626/ today (October 4), the Government Accountability Office reported that the federal government doesn't know how many labs are involved in biosafety level 3 and level 4 work, or where those labs are. Although labs working with certain "select agents" are under the oversight of the CDC, labs working with other pathogens such as SARS or Hantavirus are not required to report mishaps. "No single federal agency, according to 12 agencies' response to our survey, has the mission to track the overall numbers of BSL3 and BSL4 labs in the United States," the GAO wrote in linkurl:testimony;http://energycommerce.house.gov/cmte_mtgs/110-oi-hrg.100407.BSL.shtml submitted to the hearing. "Consequently, no agency is responsible for determining the risks associated with the proliferation of these labs. " The GAO's report counted 17 federal agencies funding BSL3 or BSL4 research.

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham